Serotonin reuptake inhibitor augmentation with N-acetylcysteine in resistant obsessive-compulsive disorder: a double-blind, randomized and controlled study

• Grant number: 12/14070-8
• Support Opportunities: Scholarships in Brazil - Doctorate (Direct)
• Start date: September 01, 2012
• End date: August 31, 2016
• Field of knowledge: Health Sciences - Medicine - Psychiatry
• Principal Investigator: Roseli Gedanke Shavitt
• Grantee: Daniel Lucas da Conceição Costa
• Host Institution: Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil

Abstract

Obsessive-Compulsive disorder (OCD) is a psychiatric condition with lifetime prevalence of 2-3%. When severe, OCD is completely incapacitating with devastating consequences for patients and their families. Although pharmacotherapy with serotonin reuptake inhibitors (SRI) is an effective treatments for many patients, a subset experience minimal relief from their symptoms with this standard treatments. The rationale for exploring the efficacy of NAC in treatment resistant OCD stems from preliminary findings from the open label Riluzole study. The primary objective of this study is to determine if N-Acetylcysteine (NAC) has efficacy as an augmentation agent in the treatment of treatment resistant OCD. Forty patients will compose the study sample: half of them will receive NAC and half will receive placebo. We predict that NAC will reduce OCD symptoms after sixteen weeks of add-on treatment as measured by the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

DA CONCEICAO COSTA, DANIEL L.; BARBOSA, VERONICA S.; REQUENA, GUARACI; SHAVITT, ROSELI G.; PEREIRA, CARLOS A. DE BRAGANCA; DINIZ, JULIANA B.. Dissecting the Yale-Brown Obsessive-Compulsive Scale severity scale to understand the routes for symptomatic improvement in obsessive-compulsive disorder. JOURNAL OF PSYCHOPHARMACOLOGY, v. 31, n. 10, p. 1312-1322, OCT 2017. (12/14070-8, 11/51485-9)

DA CONCEICAO COSTA, DANIEL LUCAS; SHAVITT, ROSELI GEDANKE; CASTRO CESAR, RAONY CASSAB; JOAQUIM, MARINES ALVES; BORCATO, SONIA; VALERIO, CAROLINA; MIGUEL, EURIPEDES CONSTANTINO; DINIZ, JULIANA BELO. Can early improvement be an indicator of treatment response in obsessive-compulsive disorder? Implications for early-treatment decision-making. JOURNAL OF PSYCHIATRIC RESEARCH, v. 47, n. 11, p. 1700-1707, NOV 2013. (11/51485-9, 12/14070-8, 11/00968-0)

COSTA, DANIEL L. C.; DINIZ, JULIANA B.; REQUENA, GUARACI; JOAQUIM, MARINES A.; PITTENGER, CHRISTOPHER; BLOCH, MICHAEL H.; MIGUEL, EURIPEDES C.; SHAVITT, ROSELI G.. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder. JOURNAL OF CLINICAL PSYCHIATRY, v. 78, n. 7, p. E766+, JUL-AUG 2017. (11/51485-9, 12/14070-8)

Academic Publications

(References retrieved automatically from State of São Paulo Research Institutions)

COSTA, Daniel Lucas da Conceição. Serotonin reuptake inhibitor augmentation with N-acetylcysteine in treatment-resistant obsessive-compulsive disorder: a double blind and controlled trial. 2016. Doctoral Thesis - Universidade de São Paulo (USP). Faculdade de Medicina (FM/SBD) São Paulo.